Pharvaris Summarizes Clinical Data Presentations at ACAAI 2026 Annual Scientific Meeting
Pharvaris presented new clinical and real-world data for its lead candidate, deucrictibant, at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting.